Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in MGUS and Smoldering Myeloma
NCT00099047Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2004
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of celecoxib oral solution in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), sponsored by National Cancer Institute. Started Nov 2004; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT00099047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099047.